Ptc Therapeutics (PTCT) Capital Expenditures (2012 - 2026)

Ptc Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 30.57% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $8.3 million (up 206.92% YoY), while the FY2025 annual figure was $8.9 million, up 12557.14% from the prior year.
• Capital Expenditures was $1.2 million for Q1 2026 at Ptc Therapeutics, down from $2.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $22.8 million in Q3 2023 to a low of -$7.4 million in Q2 2024.
• Historically, Capital Expenditures has averaged $4.2 million across 5 years, with a median of $2.4 million in 2025.
• Biggest YoY gain for Capital Expenditures was 34142.86% in 2024; the steepest drop was 92287.5% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $8.6 million in 2022, then tumbled by 35.44% to $5.6 million in 2023, then sank by 147.88% to -$2.7 million in 2024, then jumped by 189.08% to $2.4 million in 2025, then plunged by 49.58% to $1.2 million in 2026.
• The last three Capital Expenditures figures came in at $1.2 million (Q1 2026), $2.4 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.